=BioLife Solutions (BLFS) customer Kite Pharma Receives FDA Approval for Yescarta

• Headquarters: Bothell, WA
• Founded: 1987
• biolifesolutions.com

BioLife Solutions customer Kite Pharma Receives FDA Approval for Yescarta

• Kite Pharma, Inc., a wholly-owned subsidiary of Gilead Sciences, has received US FDA approval for Yescarta, the first CAR T-cell therapy for treatment of adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy.
• As announced in a July 2016 press release, BioLife executed a long-term agreement to supply its proprietary CryoStor cell freeze media to Kite Pharma. Each manufactured dose of Yescarta is frozen in CryoStor to maintain CAR T-cell viability and enable worldwide distribution.